IL294647A - AHR inhibitors and their uses - Google Patents

AHR inhibitors and their uses

Info

Publication number
IL294647A
IL294647A IL294647A IL29464722A IL294647A IL 294647 A IL294647 A IL 294647A IL 294647 A IL294647 A IL 294647A IL 29464722 A IL29464722 A IL 29464722A IL 294647 A IL294647 A IL 294647A
Authority
IL
Israel
Prior art keywords
patient
ahr
cancer
tumor
staining
Prior art date
Application number
IL294647A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ikena Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikena Oncology Inc filed Critical Ikena Oncology Inc
Publication of IL294647A publication Critical patent/IL294647A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL294647A 2020-01-10 2021-01-08 AHR inhibitors and their uses IL294647A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959246P 2020-01-10 2020-01-10
US202063128465P 2020-12-21 2020-12-21
PCT/US2021/012571 WO2021142180A1 (en) 2020-01-10 2021-01-08 Ahr inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
IL294647A true IL294647A (en) 2022-09-01

Family

ID=74595366

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294647A IL294647A (en) 2020-01-10 2021-01-08 AHR inhibitors and their uses

Country Status (12)

Country Link
US (1) US20230039711A1 (enExample)
EP (1) EP4087578A1 (enExample)
JP (1) JP2023510797A (enExample)
KR (1) KR20220125323A (enExample)
CN (1) CN115190799A (enExample)
AU (1) AU2021206696A1 (enExample)
BR (1) BR112022013673A2 (enExample)
CA (1) CA3167283A1 (enExample)
CL (1) CL2022001872A1 (enExample)
IL (1) IL294647A (enExample)
MX (1) MX2022008532A (enExample)
WO (1) WO2021142180A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3612030T3 (fi) 2017-04-21 2026-03-20 Pahr Therapeutics Inc Ahr:n indoliestäjiä ja niiden käyttötapoja
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
US12570638B2 (en) 2020-05-20 2026-03-10 Sail Biomedicines, Inc. Fused imidazole derivatives as AHR antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035288B1 (ru) * 2010-07-27 2020-05-25 Трастис Оф Бостон Юниверсити МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
RU2640913C2 (ru) * 2011-09-07 2018-01-12 Дойчес Кребсфоршунгсцентрум Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr
EA201892666A1 (ru) 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
WO2018085348A1 (en) 2016-11-03 2018-05-11 Actavalon, Inc. Substituted quinolines and methods for treating cancer
FI3612030T3 (fi) 2017-04-21 2026-03-20 Pahr Therapeutics Inc Ahr:n indoliestäjiä ja niiden käyttötapoja
SG11202001310SA (en) 2017-08-17 2020-03-30 Ikena Oncology Inc Ahr inhibitors and uses thereof
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
CA3082855A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
EP3713931B1 (en) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
MX2021004245A (es) 2018-10-16 2021-09-08 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CA3115825A1 (en) 2018-10-17 2020-04-23 Magenta Therapeutics, Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists

Also Published As

Publication number Publication date
MX2022008532A (es) 2022-09-09
CA3167283A1 (en) 2021-07-15
KR20220125323A (ko) 2022-09-14
AU2021206696A1 (en) 2022-08-04
CN115190799A (zh) 2022-10-14
US20230039711A1 (en) 2023-02-09
CL2022001872A1 (es) 2023-02-17
EP4087578A1 (en) 2022-11-16
WO2021142180A1 (en) 2021-07-15
BR112022013673A2 (pt) 2022-09-13
JP2023510797A (ja) 2023-03-15

Similar Documents

Publication Publication Date Title
WO2023060227A1 (en) Tead inhibitors and uses thereof
JP2023529214A (ja) エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療
Kam et al. A review on drug-induced dry eye disease
IL297369A (en) Methods of treating cancer
KR100862930B1 (ko) 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
US20230039711A1 (en) Ahr inhibitors and uses thereof
IL257355A (en) Selection of patients for combination therapy
IL311387A (en) Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
IL322622A (en) Preparations and methods for treating galactosemia
US20220193076A1 (en) Methods of treating breast cancer with tucatinib
CN115998871A (zh) Fabp4作为皮肤病中的治疗靶
US20240325391A1 (en) Dosage regimens for parp7 inhibitors
IL297043A (en) Drug combination including tno155 and nazaretinib
IL292378A (en) Preparations that include a dhodh inhibitor for the treatment of acute myeloid leukemia
JP2020533320A (ja) 癌療法のための免疫チェックポイント調節薬と併用したｈｄａｃ阻害薬
IL301405A (en) Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
JP2016516007A (ja) 癌治療
IL298538A (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL278596B2 (en) RAS oncoprotein inhibitors, methods for preparing and methods for using them
TW201805004A (zh) 用於預防具風險病患之阿茲海默症之㗁衍生物
IL295938A (en) Therapeutic uses of macrocyclic compounds
IL296196A (en) Methods of administering elagolix
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
IL298447A (en) Belbrafenib for use in the treatment of cancer